Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q4 2018 · 10-K
Revenue$1.60M$1.60M+17.0% vs Q4 2017 Net Income-$2.34M-$2.34MN/M vs Q4 2017 EPS Diluted-$0.04-$0.04N/M vs Q4 2017 Gross Profit$443,000−11.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived-$1,448,000N/M Free Cash Flowderived-$1,554,000N/M Margins · derivedGross margin27.6%−8.7 pt vs Q4 2017
Operating margin-147.8%−11.8 pt vs Q4 2017
Net margin-146.2%−10.8 pt vs Q4 2017
ended Jun 30, 2018 · filed Sep 26, 2018 · 88 d after period end